New study tracks how well secukinumab works for painful skin condition in daily life
NCT ID NCT06517732
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 107 adults in Russia with moderate to severe hidradenitis suppurativa (a chronic skin condition causing painful lumps) who are taking secukinumab as part of their normal care. Researchers will track how many patients see a 55% reduction in disease severity over time, using a standard scoring system. The goal is to see how well the drug works in real-world settings, outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
secukinumab
What this could lead to
If successful, this study could confirm that secukinumab works well in everyday practice for people with hidradenitis suppurativa, supporting its wider use.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes patients already prescribed the drug, and the sample size is small (107 people).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Izhevsk, 426039, Russia
-
Novartis Investigative Site
Kaliningrad, 236016, Russia
-
Novartis Investigative Site
Kaliningrad, 236029, Russia
-
Novartis Investigative Site
Kazan', 420012, Russia
-
Novartis Investigative Site
Kemerovo, 650025, Russia
-
Novartis Investigative Site
Krasnodar, 350020, Russia
-
Novartis Investigative Site
Moscow, 107076, Russia
-
Novartis Investigative Site
Moscow, 119881, Russia
-
Novartis Investigative Site
Moscow, 123182, Russia
-
Novartis Investigative Site
Moscow, 129110, Russia
-
Novartis Investigative Site
Nizhny Novgorod, 603950, Russia
-
Novartis Investigative Site
Penza, 440052, Russia
-
Novartis Investigative Site
Saint Petersburg, 197022, Russia
-
Novartis Investigative Site
Samara, 443079, Russia
-
Novartis Investigative Site
Saratov, 410028, Russia
-
Novartis Investigative Site
Stavropol, 355020, Russia
-
Novartis Investigative Site
Tula, 300053, Russia
-
Novartis Investigative Site
Ufa, 450010, Russia
-
Novartis Investigative Site
Yakutsk, 677000, Russia